The Prostate Cancer Center at Capio St. Görans hostpital in Stockholm has introduced prostate cancer diagnostics with the Stockholm3 test and targeted tissue sampling. The clinical results are seen as a breakthrough in the diagnosis of prostate cancer because more than twice as many men are found with aggressive prostate cancer and at the same time the number of unnecessary tissue samples is reduced by half. Read more in Läkartidningen.
The Stockholm3 test is a blood test that finds twice as many men with aggressive prostate cancer and at the same time reduces the number of unnecessary tissue samples by half compared with current practice. The Stockholm3 test has been tested on nearly 60,000 men and is based on research conducted at Karolinska Institutet.